It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in a number of tissues. It does not cause persistent dry cough that normally complicates ACE inhibitors therapy. This is due to the fact that it does not inhibit the breakdown of kinins.

Dosing: Adult

Hypertension: Oral: Initial: 40 mg once daily; usual maintenance dose range: 20-80 mg/day. Patients with volume depletion should be initiated on the lower dosage with close supervision.

Cardiovascular risk reduction: Oral: Initial: 80 mg once daily. Note: It is unknown whether doses <80 mg/day are associated with a reduction in risk of cardiovascular morbidity or mortality.

Dosing: Geriatric

Hypertension: Oral: Initial: 20 mg/day; usual maintenance dose range: 20-80 mg/day

Cardiovascular risk reduction: Oral: Initial 80 mg once daily

Dosing: Renal Impairment

No adjustment required; hemodialysis patients are more susceptible to orthostatic hypotension

Dosing: Hepatic Impairment

Initiate therapy with low dose; titrate slowly and monitor closely.

Canadian labeling: Recommended initial dose: 40 mg/day

Combinations ;